Pharmaceutical composition containing octreotide and preparation method thereof

Through the non-covalent interaction of octreotide and polyphenol complexes to form a complex and encapsulated in enteric-coated capsules, the problem of low oral bioavailability of octreotide is solved, and efficient absorption and safe administration forms are achieved.

CN119074937APending Publication Date: 2024-12-06CHINA PHARM UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411070622.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-06
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

Octreotide has low oral bioavailability, prior art is difficult to effectively improve its absorption, and common accelerators may lead to intestinal tissue damage and harmful risks of infection.

Method used

The complex of octreotide and polyphenols (such as tannin, gallic acid, epigallocate gallate) is used to form a stable complex through non-covalent interactions, and is encapsulated in enteric-coated capsules to improve absorption.

Benefits of technology

It significantly improves the oral absorption capacity and bioavailability of octreotide, extends the half-life and gastrointestinal retention time, reduces the preparation cost, and does not contain penetration accelerators, which has good biosafety.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119074937A_ABST
    Figure CN119074937A_ABST
Patent Text Reader

Abstract

The invention belongs to the field of pharmaceutical preparations, and discloses a pharmaceutical composition containing octreotide, the pharmaceutical composition contains an octreotide-polyphenol compound, and the polyphenol compound is selected from tannic acid, gallic acid or epigallocatechin gallate. The invention further discloses an enteric capsule of the medicine composition containing the octreotide. The enteric capsule contains the medicine composition containing the octreotide and an enteric capsule shell. The octreotide-polyphenol compound can resist degradation of trypsin and has good storage stability; the octreotide-polyphenol compound can improve the oral absorption capacity of the octreotide; the half-life period of the octreotide-polyphenol compound enteric capsule and the average residence time of gastrointestinal tracts are prolonged, the peak concentration is higher, and the bioavailability is remarkably improved. The OCT-polyphenol compound enteric capsule is high in encapsulation efficiency and drug loading capacity, and the OCT-polyphenol compound enteric capsule does not contain a penetration enhancer and has good biological safety.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of pharmaceutical preparations, and relates to a pharmaceutical composition containing octreotide and a preparation method thereof, an enteric-coated capsule of the pharmaceutical composition containing octreotide and a preparation method thereof, and particularly relates to an oral enteric-coated capsule of an octreotide-polyphenol complex and a preparation method thereof. Background Art

[0002] The oral absorption of protein and peptide drugs faces multiple physiological barriers, resulting in extremely low oral bioavailability. For example, the acidic environment of the stomach can activate pepsin, causing the hydrogen bonds and ionic bonds of proteins to be destroyed, thus changing their structure and function. The small intestine is the main site of drug absorption. However, trypsin, chymotrypsin and elastase in the intestine will cause most protein and peptide drugs to degrade. The mucus layer is the first physical barrier for biological agents to enter the blood circulation. Mucus is mainly composed of water, mucin, lipids, DNA, etc. Mucin molecules cross-link with each other to form a hydrogel network structure, which can reduce the migration rate of macromolecular drugs. Since intestinal mucus is negatively charged and lipophilic under physiological conditions, substances with neutral surfaces and hydrophilicity are conducive to penetrating the mucus layer. On the other hand, the mucus adhesion system can prolong the residence time of drugs in the intestine and promote drug absorption. In addition, the epithelial cell layer is one of the important obstacles that need to be overcome for the absorption of protein and peptide drugs. Drugs can cross the epithelial cell layer through transcellular transport and paracellular transport. Transcellular transport of drugs refers to the process by which drugs enter epithelial cells and enter the circulatory system from the basolateral side. Since protein and peptide drugs are generally hydrophilic and have a high molecular weight, they are difficult to be absorbed through the lipid bilayer. Paracellular transport refers to the process by which drugs enter the circulatory system through the interstitial spaces of epithelial cells. Epithelial cells are connected by a junction complex composed of tight junctions, adhesion junctions, and desmosomes. Tight junctions make the molecular radius larger than Substances that cannot be transported through transcellular transport hinder the absorption of macromolecular proteins and peptide drugs. At present, some common technologies to promote the oral absorption of protein drugs include adding absorption enhancers, enzyme inhibitors, nano-delivery systems, microneedles, etc.

[0003] Octreotide (OCT) is a synthetic somatostatin analogue with a longer half-life and efficacy than natural somatostatin. The molecular weight of octreotide is 1019.26 and the molecular formula is C 49 H 66 N 10 O 10S2. Octreotide can be used clinically to treat acromegaly, upper gastrointestinal bleeding, neuroendocrine tumors, pancreatitis and other diseases. Currently, OCT on the market includes three types: injection, injection microspheres and oral enteric-coated capsules. Among them, OCT injection needs to be administered three times a day. Long-term and high-frequency injections will cause mental burden on patients and increase the risk of wound infection in patients; OCT injection microspheres are administered once a month, but they are expensive, have high technical barriers, and are difficult to imitate; OCT oral enteric-coated capsules The absorption enhancer sodium caprylate is dispersed in an oily mixture with OCT, polysorbate 80, etc., and administered in the form of enteric-coated capsules. Oral administration can improve patient compliance and is the preferred method of administration in clinical practice. However, the capsule preparation is expensive and has extremely low bioavailability (0.7%). In addition, long-term use of absorption enhancers may cause intestinal tissue damage in patients and increase the risk of infection with harmful substances. Therefore, designing a simple and low-cost oral administration strategy has important clinical significance. Summary of the invention

[0004] The present invention aims to provide an octreotide (OCT)-polyphenol complex enteric-coated capsule with simple process and good safety, so as to promote the oral absorption of OCT and improve its bioavailability.

[0005] The present invention provides the following technical solutions:

[0006] A pharmaceutical composition containing OCT, wherein the pharmaceutical composition contains an OCT-polyphenol complex, wherein the polyphenol compound is selected from tannic acid (TA), gallic acid (GA) or epigallocatechingallate (EGCG).

[0007] Preferably, the polyphenol compound is TA.

[0008] Tannic acid is a natural plant polyphenol, with a brown or yellow solid powder appearance, a molecular weight of 1701.2, and a molecular formula of C 76 H 52 O 46 , the structure is shown below. TA has a glucose core connected to gallic acid through an ester bond. Polar groups such as carbonyl and hydroxyl groups on the TA main chain are connected to water-insoluble aromatic groups, so it has amphiphilicity. TA has been approved by the U.S. Food and Drug Administration (FDA) as a safe food additive.

[0009] The OCT-polyphenol complex is a complex formed by OCT and polyphenol compounds through non-covalent interaction.

[0010] The molar ratio of OCT to the polyphenol compound is 1:1 to 1:15, preferably 1:1 to 1:5, and more preferably 1:1.

[0011] Specifically, the molar ratio of OCT to the polyphenol compound can be 1:1, 1:3, 1:5, 1:7, 1:9, 1:10, or 1:15.

[0012] The pharmaceutical composition containing OCT is freeze-dried powder or granules.

[0013] A method for preparing a pharmaceutical composition containing OCT comprises: dissolving a polypeptide drug OCT in purified water to obtain an OCT solution; dissolving a polyphenol compound in purified water to obtain a polyphenol solution; adding the polyphenol solution to the OCT solution while stirring, continuing to stir after the dropwise addition is completed, and removing free OCT and polyphenol compounds by ultrafiltration to obtain an OCT-polyphenol complex.

[0014] As a further preferred embodiment of the method for preparing the pharmaceutical composition containing OCT described in the present invention, it also includes: mixing the OCT-polyphenol complex solution obtained by ultrafiltration and a lyophilization protectant, and obtaining a lyophilized powder by freeze-drying, or preparing dry particles by wet granulation of the OCT-polyphenol complex solution obtained by ultrafiltration, a filler, and a binder, or preparing dry particles by wet granulation of the OCT-polyphenol complex solution obtained by ultrafiltration, a filler, and a binder, and then mixing the dry particles with a lubricant.

[0015] An enteric-coated capsule of a pharmaceutical composition containing octreotide, wherein the enteric-coated capsule contains the pharmaceutical composition containing OCT and an enteric-coated capsule shell.

[0016] Preferably, the enteric-coated capsule is composed of the pharmaceutical composition containing OCT and an enteric-coated capsule shell.

[0017] A method for preparing enteric-coated capsules of a pharmaceutical composition containing octreotide comprises the following steps:

[0018] Step (1), dissolving the polypeptide drug OCT in purified water to obtain an OCT solution;

[0019] Step (2), dissolving the polyphenol compound in purified water to obtain a polyphenol solution;

[0020] Step (3), adding the polyphenol solution to the OCT solution while stirring, and after the addition is complete, continuing to stir, and ultrafiltration to remove free OCT and polyphenol compounds to obtain an OCT-polyphenol complex solution;

[0021] Step (4), mixing the OCT-polyphenol complex solution with a lyophilization protective agent, and preparing a lyophilized powder by freeze drying; and filling the lyophilized powder into an enteric-coated capsule shell to obtain an enteric-coated capsule;

[0022] Alternatively, the OCT-polyphenol complex solution, the binder and the filler are mixed to prepare a soft material, the soft material is sieved to prepare wet granules, the wet granules are dried and granulated to obtain dry granules, and then the dry granules are mixed with an appropriate amount of lubricant and loaded into an enteric-coated capsule shell to obtain an enteric-coated capsule.

[0023] In step (1), the concentration of OCT in the OCT solution is 0.05-5 mmol / L.

[0024] In step (2), the concentration of polyphenols in the polyphenol solution is 0.5-3 mmol / L.

[0025] In step (3), the molar ratio of OCT to the polyphenol compound is 1:1 to 1:15, preferably 1:1 to 1:5, and more preferably 1:1.

[0026] The dropping speed of the polyphenol solution is 1 mL / min to 2 mL / min.

[0027] The stirring speed is 800-1500 rpm; after the polyphenol solution is added dropwise, the stirring time is 2-3 hours.

[0028] The ultrafiltration is as follows: using an ultrafiltration tube with a molecular weight cutoff of 3kDa, ultrafiltration at 3000-4000rmp for 10-20min to remove free OCT and polyphenol compounds, and taking the upper layer of the ultrafiltration tube liquid, which is the OCT-polyphenol complex solution.

[0029] Specifically, the ultrafiltration tube may be an Ultra-4 3kDa ultrafiltration tube.

[0030] Specifically, the OCT solution is placed on a magnetic stirrer, and the polyphenol solution is added to the OCT solution while stirring. After the polyphenol solution is added dropwise, stirring is continued, and free OCT and polyphenol compounds are removed by ultrafiltration. The upper layer of the ultrafiltration tube liquid is taken to obtain an OCT-polyphenol complex solution.

[0031] In step (4), the lyophilization protective agent is one of glucose, trehalose, sucrose, lactose and mannitol.

[0032] The dosage ratio of the lyophilization protective agent to the OCT-polyphenol complex solution is 0.1:100 to 2:100 g / mL.

[0033] Preferably, the lyoprotectant is one of lactose and mannitol. When the lyoprotectant is lactose, the dosage ratio of the lyoprotectant to the OCT-polyphenol complex solution is 1:100 to 2:100 g / mL; when the lyoprotectant is mannitol, the dosage ratio of the lyoprotectant to the OCT-polyphenol complex solution is 0.1:100 to 2:100 g / mL.

[0034] The freeze drying time is 24 to 48 hours, and the freeze drying temperature is -50°C to -80°C.

[0035] The adhesive is selected from povidone K30.

[0036] The amount of the adhesive is 1wt% to 5wt% of the weight of the soft material.

[0037] The filler is selected from at least one of mannitol, lactose, microcrystalline cellulose and starch.

[0038] The amount of the filler is 1wt% to 3wt% of the weight of the soft material.

[0039] The drying temperature is 40-50° C., and the drying time is 3-5 hours.

[0040] The lubricant is selected from magnesium stearate.

[0041] The amount of the lubricant is 0.4wt% to 0.5wt% of the dry particle weight.

[0042] Specifically, the OCT-polyphenol complex solution, the binder and the filler are mixed to prepare a soft material, the soft material is passed through a 20-mesh sieve to obtain wet granules, and the wet granules are dried and passed through an 18-mesh sieve to obtain dry granules.

[0043] Principle of the invention: The invention utilizes the principle that OCT and polyphenol compounds can undergo non-covalent interactions in a natural state, and uses a magnetic stirring method to mix OCT and polyphenol compound solutions to form a stable cross-linked network complex. The non-covalent interaction forces between OCT and polyphenol compounds may include hydrogen bonds, electrostatic forces, hydrophobic bonds, and van der Waals forces. Among them, hydrogen bonds may occur between the amide groups of OCT and the phenolic hydroxyl groups of polyphenol compounds; electrostatic interactions may occur between the positively charged groups in OCT and the negatively charged hydroxyl groups of polyphenol compounds; and hydrophobic interactions may occur between the hydrophobic groups of OCT and the aromatic rings of polyphenol compounds.

[0044] Beneficial effects of the present invention:

[0045] (1) In vitro experiments showed that the OCT-polyphenol complex can resist trypsin degradation and has good storage stability; in vivo intestinal perfusion experiments, cell uptake and transmembrane transport experiments proved that the OCT-polyphenol complex can improve the oral absorption capacity of OCT; pharmacokinetic experimental results showed that the half-life and average gastrointestinal residence time of the OCT-polyphenol complex enteric-coated capsules were prolonged, the peak concentration was higher, and the bioavailability was significantly improved.

[0046] (2) The preparation process of the OCT-polyphenol complex enteric-coated capsules prepared by the present invention is simple, the cost is low, the industrial conversion value is good, and it conforms to the concept of "green environmental protection". The OCT-polyphenol complex has high encapsulation efficiency and drug loading, and the OCT-polyphenol complex enteric-coated capsules do not contain a permeation enhancer, have good biosafety, and have competitive advantages compared with commercially available drugs. BRIEF DESCRIPTION OF THE DRAWINGS

[0047] Figure 1 This is the UV spectrum of the OCT-TA complex.

[0048] Figure 2 This is the UV spectrum of the OCT-GA complex.

[0049] Figure 3 This is the UV spectrum of the OCT-EGCG complex.

[0050] Figure 4 This is the infrared spectrum of the OCT-TA complex.

[0051] Figure 5 Infrared spectrum of OCT-GA complex.

[0052] Figure 6 This is the infrared spectrum of OCT-EGCG complex.

[0053] Figure 7 This is the fluorescence emission spectrum of the OCT-TA complex.

[0054] Figure 8 This is the fluorescence emission spectrum of the OCT-GA complex.

[0055] Fig. 9 This is the fluorescence emission spectrum of the OCT-EGCG complex.

[0056] Fig.10 Stern-Volmer plot of OCT-TA complex at 298, 304, and 310K.

[0057] Fig.11 Stern-Volmer plot of OCT-GA complex at 298, 304, and 310K.

[0058] Fig.12 Stern-Volmer plot of OCT-EGCG complex at 298, 304, and 310K.

[0059] Fig.13 Double logarithmic curve of OCT-TA complex at 298, 304, and 310K.

[0060] Fig.14 Double logarithmic curve of OCT-GA complex at 298, 304, and 310K.

[0061] Fig.15 Double logarithmic curve of OCT-EGCG complex at 298, 304, and 310K.

[0062] Fig.16 The encapsulation efficiency and drug loading of OCT-TA complexes with different molar ratios are shown in Figure 2.

[0063] Fig.17 This is a diagram of the OCT-TA complex resisting trypsin degradation.

[0064] Fig.18 This is a scanning electron micrograph of the OCT-TA complex.

[0065] Fig.19 This is the storage stability diagram of OCT-TA complex.

[0066] Fig. 20 This is a graph showing the cell viability of the OCT-TA complex examined by the MTT method.

[0067] Fig.21 This is the result of laser confocal microscopy experiment for the control group after 2h and 4h of drug administration.

[0068] Fig. 22 The results of laser confocal microscopy experiments were shown for the 2h and 4h drug administration groups.

[0069] Fig.23 is the transmembrane resistance of Caco-2 cells at different growth times.

[0070] Fig.24 is the P of FITC-OCT and FITC-OCT-TA complexes app value.

[0071] Fig.25 This is the blood drug concentration-time curve of subcutaneous injection of OCT, oral administration of OCT-TA enteric-coated capsules and OCT enteric-coated capsules in rats. DETAILED DESCRIPTION

[0072] The raw materials or reagents used in the present invention are all commercially available. The formation of the OCT-TA complex is characterized by ultraviolet spectroscopy, infrared spectroscopy, and fluorescence spectroscopy, and the information of the interaction force between the two is investigated, and the encapsulation rate, drug loading, anti-protease degradation ability, in vitro release behavior and stability of the complex are investigated. The oral absorption capacity of the OCT-TA complex is evaluated by a rat unidirectional intestinal perfusion experiment, cell uptake, and transmembrane transport experiment. Considering the acid resistance of polypeptide drugs, the present invention solidifies the complex and puts it into an enteric-coated capsule for pharmacokinetic study. The solidification methods of the drug include freeze drying, wet granulation, etc. Freeze drying technology uses a sublimation method to dehydrate the drug, and the low-temperature production process used in freeze drying can effectively maintain the activity of biological agents. Wet granulation is a method of preparing particles by aggregating powders together with a binder. The particles prepared by this method have a beautiful appearance and can improve the fluidity of the drug. The present invention is further described below in conjunction with specific examples.

[0073] Example 1

[0074] Preparation and characterization of OCT-polyphenol complexes

[0075] 1 mg of OCT was weighed and dissolved in 1 mL of purified water to obtain an OCT solution with a concentration of 0.98 mmol / L; according to the molar ratio of OCT to polyphenol compounds (TA, GA, EGCG) of 1:1, polyphenol compounds were weighed and dissolved in 1 mL of purified water to obtain a polyphenol solution (the concentrations of TA, GA, and EGCG were all 0.98 mmol / L); the OCT solution was placed on a magnetic stirrer, and the polyphenol solution was added dropwise to the OCT solution while stirring (at a speed of 1000 rpm), and the dropping speed of the polyphenol solution was 1 mL / min. After the dropwise addition was completed, the speed was maintained at 1000 rpm and magnetic stirring was performed for 3 hours; then the mixture was transferred to an Ultra-43 kDa ultrafiltration tube, ultrafiltered at 4000 rpm for 10 minutes to remove free drugs, and the upper layer of the ultrafiltration tube was taken, which was the OCT-polyphenol complex (OCT-TA complex, OCT-GA complex, and OCT-EGCG complex, respectively) solution.

[0076] The OCT-polyphenol complex was characterized by UV, IR and fluorescence spectroscopy.

[0077] Figure 1 , Figure 2 , Figure 3 These are the UV spectra of the interaction between OCT and polyphenol compounds TA, GA, and EGCG.

[0078] After OCT and polyphenols formed a complex, the maximum absorption wavelength of OCT in the UV spectrum shifted to the blue, indicating that the addition of polyphenols

[0079] The hydrophobicity of the microenvironment around OCT was enhanced, indicating that a complex was formed between OCT and TA, GA, and EGCG.

[0080] Figure 4 , Figure 5 , Figure 6 The infrared spectra of OCT interacting with polyphenol compounds TA, GA, and EGCG, respectively. After OCT and polyphenols form a complex, the C=O absorption peak of the OCT amide I band, the NH stretching vibration peak, and the phenolic hydroxyl stretching vibration peak of the polyphenol compounds all shift, indicating that hydrogen bonding interactions occur between OCT and TA, GA, and EGCG.

[0081] 1 mg OCT was weighed and dissolved in 1 mL purified water to obtain a 0.98 mmol / L OCT solution; the corresponding mass of TA, GA or EGCG was weighed and dissolved in purified water to obtain TA solution, GA solution, and EGCG solution, respectively (the volume of the three polyphenol solutions was 1 mL), and the concentration gradients of the TA solution were 0.5, 1, 1.5, 2, 2.5, and 3 mmol / L, respectively; the concentration gradients of the GA solution were 0.5, 1, 1.5, 2, 2.5, and 3 mmol / L, respectively; and the concentration gradients of the EGCG solution were The concentrations of TA, GA or EGCG solutions were added dropwise into the OCT solution while stirring (at a speed of 1000 rpm). The addition rate was 1 mL / min. After the addition was completed, the rotation speed was maintained at 1000 rpm and magnetic stirring was performed for 3 h to prepare solutions containing OCT-polyphenol complexes (OCT-TA complex, OCT-GA complex, OCT-EGCG complex, respectively), and fluorescence spectral scanning was performed.

[0082] OCT has endogenous fluorescence because it contains the chromophores tryptophan and phenylalanine. When the microenvironment around the chromophore changes, the emission spectrum of OCT will change. Figure 7 , Figure 8 , Fig. 9 As shown, at a temperature of 298 K, as the concentration of polyphenols increased, the maximum fluorescence intensity of OCT gradually decreased, that is, fluorescence quenching occurred.

[0083] Fluorescence quenching includes two types: static quenching and dynamic quenching. Static quenching is caused by the formation of complexes between molecules, while dynamic quenching is caused by collisions between molecules. The K q and K sv Value, determine the quenching type, the Stern-Volmer equation is as follows:

[0084]

[0085] F0: fluorescence intensity without quencher; F: fluorescence intensity with quencher; K q : fluorescence quenching rate constant; Q: concentration of quencher; K sv : dynamic quenching constant; τ0: average lifetime of drug molecules without quencher (τ0 = 10 -8 s).

[0086] The results are shown in Table 1 and Fig.10 , Fig.11 , Fig.12 As shown, the K of OCT-polyphenol complex q The value is greater than the maximum dynamic quenching constant 2×10 10 , K sv It decreased with the increase of temperature, indicating that OCT formed complexes with TA, GA, and EGCG, respectively, leading to static quenching of OCT, that is, OCT formed complexes with TA, GA, and EGCG, respectively.

[0087] Table 1. K of OCT-polyphenol complexes at 298K, 304K, and 310K q and K sv value

[0088]

[0089] The binding constant and number of binding sites of the OCT-polyphenol complex can be further calculated by the double logarithmic equation, which is as follows:

[0090]

[0091] K a : binding constant; n: number of binding sites

[0092] The results are shown in Table 2 and Fig.13 , Fig.14 , Fig.15 As shown in Figure 2, the K values ​​of the three OCT-polyphenol complexes at three temperatures: 298 K, 304 K, and 310 K. a The order of values ​​is OCT-TA>OCT-GA>OCT-EGCG, and the n value is greater than 1, indicating that there is at least one binding site between OCT and the three polyphenol complexes, and the interaction between OCT and TA is the strongest, which further verifies the formation of OCT-TA complex.

[0093] Table 2. K values ​​of OCT-polyphenol complexes at 298K, 304K, and 310K q and K sv value

[0094]

[0095] Example 2

[0096] Investigation of encapsulation efficiency and drug loading of OCT-TA, OCT-GA and OCT-EGCG complexes

[0097] According to Example 1, OCT-TA, OCT-GA and OCT-EGCG complexes with a molar ratio of OCT to polyphenol compounds of 1:1 were prepared, and the free OCT concentration in the lower layer of the centrifuge tube was tested by HPLC. The calculation formula is as follows:

[0098] Encapsulation efficiency (EE%) = (1-unencapsulated OCT mass / total OCT amount) × 100% Drug loading (DL%) = encapsulated OCT mass in the complex / (total OCT amount + total TA amount) × 100% The results are shown in Table 3. Among the three OCT-polyphenol complexes, the OCT-TA complex has the highest encapsulation efficiency, and the OCT-TA complex has the strongest binding force, so TA was selected as the optimal polyphenol for subsequent research.

[0099] Table 3. Encapsulation efficiency and drug loading of OCT-TA, OCT-GA and OCT-EGCG (mean ± SD, n = 3)

[0100]

[0101] Example 3

[0102] Investigation of encapsulation efficiency and drug loading of OCT-TA complex

[0103] The OCT-TA complex was prepared with reference to Example 1, specifically as follows: 1 mg of OCT was weighed and dissolved in 1 mL of purified water to obtain an OCT solution with a concentration of 0.98 mmol / L; TA was weighed according to the molar ratio of OCT to TA of 1:1, 1:3, 1:5, 1:7, 1:9, 1:10 and 1:15, and 1 mL of TA solutions of different concentrations were prepared with purified water; the OCT solution was placed on a magnetic stirrer, and the TA solution was added dropwise to the OCT solution while stirring (at a speed of 1000 rpm), the dropping speed of the TA solution was 1 mL / min, and after the dropwise addition was completed, the speed was maintained at 1000 rpm and magnetic stirring was performed for 3 hours; then the mixture was transferred to an Ultra-4 3 kDa ultrafiltration tube, ultrafiltered at 4000 rpm for 10 minutes, the free OCT concentration in the liquid in the lower layer of the ultrafiltration tube was tested, and the encapsulation efficiency and drug loading of the OCT-TA complex were calculated.

[0104] The results are shown in Table 4 and Fig.16As shown, OCT-TA complexes with different molar ratios all have high encapsulation efficiency, among which the molar ratio of 1:1 has the highest drug loading capacity, so 1:1 is selected as the optimal formulation.

[0105] Table 4. Encapsulation efficiency and drug loading of OCT-TA complexes prepared with different molar ratios of OCT and TA (mean ± SD, n = 3)

[0106]

[0107] Example 4

[0108] Study on the ability of OCT-TA complex to resist trypsin degradation

[0109] According to Example 1, OCT-TA, OCT-GA and OCT-EGCG complexes with a molar ratio of OCT to polyphenol compounds of 1:1 were prepared, and OCT-TA, OCT-GA, OCT-EGCG complex or OCT was placed in a PBS solution (pH 6.8) containing trypsin, and the final concentration of the four solutions (in terms of OCT) was 0.1 mg / mL, the trypsin concentration was 20 mg / mL, and placed in a water bath oscillator, reacted at 37°C and 100 rpm for 3 hours, and 250 μL was sampled at 0, 0.5, 1, 1.5, 2, 2.5, and 3 hours, respectively, and the reaction was terminated with an equal volume of 0.1 mol / L hydrochloric acid. The OCT content in the solution was tested by HPLC, and the remaining percentage of trypsin degradation of OCT and OCT-TA, OCT-GA and OCT-EGCG complexes was calculated.

[0110] The results are as follows Fig.17 As shown in the figure, after 3 hours of trypsin treatment, the remaining amount of OCT was 49.26%, and the remaining amount of OCT-TA complex was 85.22%, which was significantly higher than the remaining amount of OCT (P<0.001). The remaining amounts of OCT-GA complex and OCT-EGCG complex were 49% and 49.6%, respectively, which were not significantly different from the remaining amount of OCT, indicating that TA can improve the anti-trypsin degradation ability of OCT.

[0111] Example 5

[0112] Scanning electron microscopy of OCT-TA complex

[0113] An OCT-TA complex with a molar ratio of OCT to TA of 1:1 was prepared by referring to Example 1. The OCT-TA complex solution was freeze-dried, a small amount of the freeze-dried sample of the OCT-TA complex was taken and fixed on a conductive adhesive, gold was sprayed under vacuum for 30 s, and photos were taken at an acceleration voltage of 20 KV.

[0114] The results of SEM observations are as follows Fig.18As shown, the OCT-TA complex exhibits a cross-linked network structure, which is beneficial to the stability of the OCT-TA complex.

[0115] Example 6

[0116] Study on the storage stability of OCT-TA complex

[0117] An OCT-TA complex solution with a molar ratio of OCT to TA of 1:1 was prepared by referring to Example 1. The OCT-TA complex solution was placed at 25° C. and 4° C. for two weeks, and the change in OCT content was tested by HPLC on the 1st, 4th, 7th and 14th day.

[0118] like Fig.19 As shown, after the OCT-TA complex was placed at 25°C and 4°C for two weeks, the OCT content did not change significantly, indicating that the OCT-TA complex has good storage stability.

[0119] Example 7

[0120] Study on intestinal absorption of OCT-TA complex

[0121] The intestinal absorption of OCT-TA complex was investigated by a one-way intestinal perfusion experiment. The specific steps are as follows:

[0122] An OCT-TA complex with a molar ratio of OCT to TA of 1:1 was prepared by referring to Example 1. The OCT-TA complex solution and the OCT solution were prepared using Krebs-Ringer solution, respectively, so that the final concentration of the two solutions (in terms of OCT) was 0.05 mg / mL, which were used as perfusion fluids.

[0123] Six SD rats (240±20g) were randomly divided into two groups according to their body weight: OCT-TA complex preparation group and free OCT control group. All rats were fasted for 12h before the experiment, anesthetized with chloral hydrate (3.3%), and a small incision was made in the abdomen of the rat using surgical scissors to peel out the jejunal segment of the rat. Cannulae were inserted at both ends of the jejunum, and the intestinal contents of the rat were flushed with normal saline. A peristaltic pump was connected to pump the perfusion fluid into the intestinal segment at a flow rate of 1mL / min for 90min; the flow rate was reduced to 0.2mL / min for 0.5 hours of equilibrium, and replaced with a perfusion fluid of known weight, which was perfused at a flow rate of 0.2mL / min for 90min. A vial of known weight was placed at the perfusion outlet to receive it. After the experiment, the length and inner diameter of the jejunal segment were tested, the concentration of the perfusion fluid in the vial was tested by HPLC, and the intestinal permeability coefficient P was calculated. app and the absorption rate constant K a , the calculation formula is as follows:

[0124]

[0125] C in is the concentration of the inlet perfusate (mg / mL); C out is the concentration of the outlet perfusate (mg / mL); V in V is the volume of the inlet perfusate after correction (mL); out is the volume of the outlet perfusate after correction (mL); l is the length of the intestinal segment (cm); r is the inner diameter of the intestinal segment (cm); Q is the perfusion rate (mL / min).

[0126] The results are shown in Table 5. The K a and P app The values ​​were significantly higher than those in the control group, indicating that TA can improve the intestinal absorption capacity of OCT.

[0127] Table 5. Intestinal permeability results of OCT-TA complex and OCT (mean ± SD, n = 3)

[0128]

[0129] Example 8

[0130] Study on the cytotoxicity of OCT-TA complex

[0131] DMEM culture medium (serum-free) containing OCT-TA complex (refer to Example 1, prepared according to a molar ratio of OCT and TA of 1:1), OCT or TA was prepared, and the final concentrations of OCT-TA complex (in terms of OCT) were 200, 100, 50, 25, 12.5, 6.25, 3.125, and 1.5625 μg / mL, respectively, the final concentrations of OCT were 200, 100, 50, 25, 12.5, 6.25, 3.125, and 1.5625 μg / mL, respectively, and the final concentrations of TA were 200, 100, 50, 25, 12.5, 6.25, 3.125, and 1.5625 μg / mL, respectively.

[0132] The cytotoxicity of OCT-TA complex was tested by MTT method. Caco-2 cells in logarithmic growth phase were digested and counted, and 5000 cells were inoculated in each well of 96-well plate. The 96-well plate was placed in an incubator and cultured for 48 hours at 37°C and 5% CO2. The original DMEM complete medium was discarded, and 200 μL of DMEM medium containing OCT-TA complex, OCT or TA was added to the 96-well plate in the experimental group. Five parallel wells were set for each concentration gradient, and blank wells (no cells were inoculated) and control wells (no co-incubation with drugs) were set. The 96-well plate was placed in an incubator for 48 hours, and then 20 μL of MTT was added to each well, and it was placed in an incubator for 4 hours in the dark. The culture medium was discarded, 200 μL of DMSO was added to the 96-well plate, and the 96-well plate was placed on a shaker at 120 rpm for 15 minutes. The absorbance (A) at 570 nm was tested with an ELISA reader, and the cell survival rate was calculated as follows:

[0133] Cell survival rate (%) = (A 实验 -A 空白 ) / (A 对照 -A 空白 )×100%

[0134] The results of MTT assay are as follows Fig. 20 As shown, after the OCT-TA complex, OCT, and TA interacted with Caco-2 cells for 48 hours, the cell survival rates were all greater than 90%, indicating that the OCT-TA complex, OCT, and TA all had good cell safety.

[0135] Example 9

[0136] Investigation of cellular uptake of FITC-OCT-TA complex

[0137] Referring to Example 1, OCT was replaced with an equal mass of fluorescein isothiocyanate-labeled octreotide (FITC-OCT), and a FITC-OCT-TA complex was prepared at a molar ratio of FITC-OCT to TA of 1:1.

[0138] DMEM culture medium containing FITC-OCT or FITC-OCT-TA complex was prepared, and the final concentration of FITC-OCT was 50 μg / mL.

[0139] Laser confocal microscopy was used to investigate the cellular uptake ability of the OCT-TA complex. Caco-2 cells in the logarithmic growth phase were digested and counted, and 100,000 cells were seeded in each well of the confocal dish. The confocal dish was placed in an incubator and cultured at 37°C and 5% CO2 until the confluence reached about 80%; the culture medium was discarded, the cells were washed three times with PBS, and replaced with DMEM culture medium containing FITC-OCT or FITC-OCT-TA complex, which was placed in the confocal dish and cultured in the incubator for 2h and 4h, respectively; the culture medium was discarded, the cells were washed three times with PBS, 1mL of 4% paraformaldehyde fixative was added, and the cells were fixed at room temperature for 10min; the paraformaldehyde fixative was discarded, the cells were washed three times with PBS, 300μL of DAPI staining solution was added, and the cells were stained at room temperature for 10min; the DAPI staining solution was discarded, the cells were washed three times with PBS, 200μL of PBS was added to the confocal dish, and the cell uptake behavior was observed under a laser microscope.

[0140] The confocal imaging results are as follows Fig.21 and Fig. 22 As shown, the cellular uptake of the drug is time-dependent; at 2h and 4h after administration, the fluorescence intensity of the OCT-TA complex preparation group was higher than that of the OCT control group, indicating that TA can promote the cellular uptake of OCT.

[0141] Example 10

[0142] Investigation of cellular transport of FITC-OCT-TA complex

[0143] Referring to Example 1, OCT was replaced with an equal mass of fluorescein isothiocyanate-labeled octreotide (FITC-OCT), and a FITC-OCT-TA complex was prepared at a molar ratio of FITC-OCT to TA of 1:1.

[0144] DMEM culture medium containing FITC-OCT or FITC-OCT-TA complex was prepared, and the final concentration of FITC-OCT was 50 μg / mL.

[0145] Caco-2 cells in the logarithmic growth phase were digested and counted, and a cell suspension prepared with 400 μL DMEM complete medium was added to the AP (Apical side) end of the Transwell chamber. 80,000 Caco-2 cells were inoculated in each well, and 600 μL DMEM complete medium was added to the BL (Basolateral side). Three blank Transwell polycarbonate membrane chambers were set up, and 400 μL and 600 μL DMEM complete medium were added to the AP and BL ends respectively as blank controls. The Transwell culture plate was cultured at 37°C and 5% CO2 for 21 days. The medium was changed every two days for the first 7 days, and every day after one week. The transepithelial electrical resistance (TEER) was tested using a transepithelial electrical resistance meter on the 1st, 5th, 10th, 15th, and 21st days to determine whether tight junctions were formed. The calculation formula for TEER is as follows:

[0146] TEER (Ω·cm 2 )=(R 测试 -R 空白 )×A

[0147] R 测试 is the resistance of the monolayer cell, R 空白 is the resistance value of the blank hole, and A is the area of ​​the polycarbonate single-layer film.

[0148] The TEER test results are shown in Fig.23 As shown in Figure 2, the TEER value of Caco-2 monolayer cells increased with the increase of culture time. After 21 days of culture in Transwell, the TEER value reached 606.66Ω·cm 2 , greater than 300Ω·cm 2 , which can be used in cell transport experiments.

[0149] After the transmembrane resistance transport model was successfully constructed, the medium at the AP and BL ends of the Transwell culture plate was discarded, and the AP and BL ends of the Transwell culture plate were washed three times with HBSS buffer. 400 μL HBSS buffer was added to the AP end, and 600 μL HBSS buffer was added to the BL end, and the plate was placed in an incubator for 30 min. The HBSS buffer was discarded, 400 μL FITC-OCT or FITC-OCT-TA complex DMEM medium was added to the AP end, and 600 μL HBSS buffer was added to the BL end, and the plate was placed in an incubator for 30 min. 200 μL of samples were taken from the BL side at 0.5, 1, 1.5, 2, 2.5, and 3 h, respectively, and the same volume of HBSS buffer was added. The fluorescence intensity of the samples was detected using a multi-mode microplate, and the P of the FITC-OCT and FITC-OCT-TA complex solutions was calculated. app value.

[0150] Transmembrane transport results such as Fig.24 As shown, 4 hours later, the FITC-OCT-TA complex preparation group P app The value was significantly higher than that of the control group (P<0.01), indicating that TA can improve the transmembrane transport ability of OCT.

[0151] Embodiment 11

[0152] Preparation of OCT-TA complex granules enteric-coated capsules by wet granulation

[0153] An OCT-TA complex solution with a molar ratio of OCT to TA of 1:1 was prepared according to Example 1, and a soft material was prepared by mixing the OCT-TA complex solution, povidone K30 and microcrystalline cellulose, wherein the amounts of OCT-TA complex, povidone K30 and microcrystalline cellulose were 4wt%, 3wt% and 93wt% of the weight of the soft material, respectively; the soft material was sieved through a 20-mesh sieve to obtain wet granules, and the wet granules were dried in an oven at 45°C for 4h; the dried granules were sieved through an 18-mesh sieve for granulation, and then mixed with 0.4wt% of magnesium stearate by weight of the dry granules and loaded into an enteric capsule shell to obtain OCT-TA complex granule enteric capsules.

[0154] Example 12

[0155] Prescription screening of freeze-drying protective agent for OCT-TA complex

[0156] According to Example 1, an OCT-TA complex solution with a molar ratio of OCT to TA of 1:1 was prepared, and lyophilized protective agents glucose, sucrose, trehalose, lactose, and mannitol were added respectively. The dosage ratio of each lyophilized protective agent to the OCT-TA complex solution was 0.1:100, 0.5:100, 1:100, and 2:100 g / mL (corresponding to 0.1%, 0.5%, 1%, and 2% in Table 6), respectively. The mixture was freeze-dried at -55°C for 48 h using a freeze dryer to obtain a lyophilized preparation of the OCT-TA complex. The appearance, solubility, and color of the lyophilized preparation were observed.

[0157] The types and contents of freeze-dried protective agents were screened based on appearance, resolubility, and color. The freeze-dried samples were scored using the following criteria: a full and smooth sample was scored as 2; a slightly wrinkled sample was scored as 1; a severely wrinkled sample was scored as 0. A sample that dissolved quickly was scored as 2; a sample that dissolved slowly was scored as 1; a sample that was poorly soluble was scored as 0. A sample with no color difference was scored as 2; a sample with a slight color difference was scored as 1; a sample with a significant color difference was scored as 0.

[0158] The results are shown in Table 6. When the amount of mannitol was 0.5% or more of the OCT-TA complex solution, the freeze-dried sample had the highest score, and 0.5% mannitol was selected as the optimal formulation of the freeze-drying protectant.

[0159] Table 6. Lyoprotectant scoring table

[0160]

[0161] Embodiment 13

[0162] Pharmacokinetics of OCT-TA complex

[0163] Twelve male SD rats were randomly divided into three groups (n=4). The rats were fasted for 12 hours before the experiment and had free access to water.

[0164] Subcutaneous OCT injection group: OCT solution was injected subcutaneously at a dosage of 0.1 mg / kg.

[0165] OCT-TA enteric-coated capsule group: OCT-TA complex enteric-coated capsules were orally administered, and the dosage of OCT-TA complex was 4.221 mg / kg. Preparation method of OCT-TA enteric-coated capsules: According to Example 1, an OCT-TA complex solution with a molar ratio of OCT to TA of 1:1 was prepared, and 0.5% mannitol was added to the OCT-TA complex solution as a lyophilization protective agent, and freeze-dried at -55°C for 48 hours using a freeze dryer, and the freeze-dried OCT-TA complex was loaded into purchased rat enteric-coated capsules.

[0166] OCT enteric-coated capsule group: OCT enteric-coated capsules were orally administered, and the dosage of OCT was 4.221 mg / kg. Preparation method of OCT enteric-coated capsules: Weigh an appropriate amount of OCT and put it into purchased rat enteric-coated capsules.

[0167] After administration, blood (0.5 mL) was collected from the eye sockets at 10, 20, 30, 40 min, 1, 1.5, 2, 3, 4, 6, 8, 10, and 24 h respectively and placed in a centrifuge tube. The inside of the centrifuge tube was infiltrated with 3.8% sodium citrate and centrifuged at 3000 rpm for 10 min. The upper plasma sample was collected, and the blood drug concentration of OCT was tested by Elisa. The drug-time curve was drawn, and the pharmacokinetic parameters were calculated by PKSolver.

[0168] The results of pharmacokinetic experiments are shown in Table 7 and Fig.25 As shown in Figure 2, compared with OCT enteric-coated capsules, OCT-TA enteric-coated capsules can prolong the half-life of OCT in vivo. 1 / 2 ), improve the time to peak drug concentration (T max ) and peak concentration (Peak concentration, C max ), prolonging the mean residence time (MRT) in the body. The AUC value (Area under curve, AUC) of OCT-TA enteric-coated capsules was significantly higher than that of OCT enteric-coated capsules, and the oral relative bioavailability was 6.07%, which was 1.74 times that of OCT enteric-coated capsules, indicating that OCT-TA enteric-coated capsules can promote the absorption of OCT in the body.

[0169] Table 7. Pharmacokinetic parameters of subcutaneous group, oral preparation group and oral control group (mean ± SD, P < 0.001)

[0170]

Claims

1. A pharmaceutical composition containing octreotide, Features: The pharmaceutical composition contains octreotide-polyphenol complex, and the polyphenol compound is selected from tannic acid, gallic acid or epigallocatechin gallate.

2. The pharmaceutical composition containing octreotide according to claim 1, Features: The polyphenol compound is tannic acid.

3. The pharmaceutical composition containing octreotide according to claim 1, Features: The molar ratio of octreotide to the polyphenol compound is 1:1 to 1:15, preferably 1:1 to 1:5, and more preferably 1:

1.

4. A method for preparing the pharmaceutical composition containing octreotide according to claim 1, Features: include: dissolving octreotide in purified water to obtain an octreotide solution; dissolving the polyphenol compound in purified water to obtain a polyphenol solution; The polyphenol solution is added to the octreotide solution while stirring. After the addition is completed, stirring is continued and ultrafiltration is performed to obtain an octreotide-polyphenol complex.

5. A method for preparing a pharmaceutical composition containing octreotide according to claim 4, Features: The octreotide-polyphenol complex solution obtained by ultrafiltration and the lyophilization protective agent are mixed, and freeze-dried to obtain lyophilized powder, or the octreotide-polyphenol complex solution obtained by ultrafiltration, the filler, and the binder are wet granulated to obtain dry granules, or the octreotide-polyphenol complex solution obtained by ultrafiltration, the filler, and the binder are wet granulated to obtain dry granules, and then the dry granules are mixed with a lubricant.

6. An enteric-coated capsule containing a pharmaceutical composition of octreotide, Features: The enteric-coated capsule contains the pharmaceutical composition containing octreotide according to claim 1 and an enteric-coated capsule shell.

7. A method for preparing the enteric-coated capsules of the pharmaceutical composition containing octreotide according to claim 6, Features: Here are the steps: Step (1), dissolving octreotide in purified water to obtain an octreotide solution; Step (2), dissolving the polyphenol compound in purified water to obtain a polyphenol solution; Step (3), adding the polyphenol solution to the octreotide solution while stirring, and after the dropwise addition is completed, continuing stirring, and ultrafiltration to remove free octreotide and polyphenol compounds to obtain an octreotide-polyphenol complex solution; Step (4), mixing the octreotide-polyphenol complex solution with the lyophilization protective agent, and preparing a lyophilized powder by freeze drying; and filling the lyophilized powder into an enteric-coated capsule shell to obtain an enteric-coated capsule; Or the octreotide-polyphenol complex solution, the binder and the filler are mixed to prepare a soft material, the soft material is sieved to prepare wet granules, the wet granules are dried and granulated to obtain dry granules, and then the dry granules are mixed with an appropriate amount of lubricant and loaded into an enteric-coated capsule shell to obtain an enteric-coated capsule.

8. The method for preparing the enteric-coated capsule of the pharmaceutical composition containing octreotide according to claim 7, Features: In step (1), the concentration of octreotide in the octreotide solution is 0.05-5 mmol / L; in step (2), the concentration of polyphenol in the polyphenol solution is 0.5-3 mmol / L; in step (3), the stirring speed is 800-1500 rpm; after the polyphenol solution is added dropwise, the stirring time is 2-3 hours; and the ultrafiltration is performed by using an ultrafiltration tube with a molecular weight cutoff of 3 kDa and ultrafiltration at 3000-4000 rpm for 10-20 minutes.

9. The method for preparing the enteric-coated capsule of the pharmaceutical composition containing octreotide according to claim 7, Features: In step (4), the lyoprotectant is one of glucose, trehalose, sucrose, lactose and mannitol; the dosage ratio of the lyoprotectant to the octreotide-polyphenol complex solution is 0.1:100 to 2:100 g / mL; The adhesive is selected from polyvinylpyrrolidone K30; the amount of the adhesive is 1wt% to 5wt% of the weight of the soft material. The filler is selected from at least one of mannitol, lactose, microcrystalline cellulose and starch; the amount of the filler is 1wt% to 3wt% of the weight of the soft material; The lubricant is selected from magnesium stearate; the amount of the lubricant is 0.4wt% to 0.5wt% of the dry particle weight.

10. A method for preparing enteric-coated capsules of a pharmaceutical composition containing octreotide according to claim 7 or 9, Features: In step (4), the lyoprotectant is one of lactose and mannitol; when the lyoprotectant is lactose, the amount ratio of the lyoprotectant to the octreotide-polyphenol complex solution is 1:100 to 2:100 g / mL; when the lyoprotectant is mannitol, the amount ratio of the lyoprotectant to the octreotide-polyphenol complex solution is 0.1:100 to 2:100 g / mL.